Lilly Expands Pre-Approval Access to Retatrutide

Eli Lilly has begun providing more information about how patients can obtain retatrutide, its investigational GLP-1, GIP and glucagon triple receptor agonist, before the drug is approved. The move comes after reporting that a single 79-year-old patient had received the compound through the FDA's compassionate use program.

Retatrutide, sometimes called a “triple-G” candidate, is a single molecule that acts on all three incretin-related receptors. In the TRIUMPH-1 Phase 3 trial reported in May, the 12mg dose produced an average 28% weight loss over 80 weeks among participants who stayed on treatment. The compound remains investigational and has not been approved by any regulator.

Who Can Apply

The eligibility criteria were confirmed by a Lilly spokesperson to Reuters. Applicants must be aged 18 or older; have refractory obesity despite tolerating the highest approved dose of an obesity therapy; have at least two serious or life-threatening obesity-related complications for which they are receiving care; and be unable to participate in an ongoing clinical trial of retatrutide or another investigational treatment.

A treating physician must determine that a patient meets the criteria and submit a request to Lilly. The company said it is actively reviewing requests from health care providers.

What Remains Unclear

Clinicians have described the criteria as vague. One open question is what Lilly counts as a serious or life-threatening obesity-related complication. Obstructive sleep apnea, advanced liver disease and heart failure are among the conditions that might qualify, but the company has not specified.

The criteria also contrast with other compassionate use programs, which generally publish more detailed eligibility guidance. Refractory obesity is sometimes defined as the inability to lose and maintain more than 5% of body weight despite treatment, including the highest approved dose of weight loss medication, but that definition is not universal.

The Broader Regulatory Picture

The early access expansion sits alongside an active dispute between Lilly and the FDA over how retatrutide should be classified. Lilly argues the drug is a biologic, which would grant it 12 years of market exclusivity. The FDA considers it a peptide, which would provide roughly five years of protection. The outcome matters beyond generic competition: a biologic designation would make it harder for compounding pharmacies to produce alternatives. Public Citizen has reported that at least 14 people have been hospitalised after taking gray-market versions of retatrutide, which are sold online and typically labelled for research use only.

Lilly plans to submit retatrutide for FDA approval in early 2027. If the review follows a conventional timeline, the compound would not be launched before late 2027 at the earliest. Regulators in other jurisdictions, including Australia and Europe, monitor FDA proceedings as part of their own scheduling and enforcement processes.

What to Watch Next

The items most likely to shape the next phase are the FDA's classification decision, the outcome of Lilly's remaining TRIUMPH program studies, and whether the expanded access program publishes more specific eligibility guidance. For researchers tracking the triple-agonist class, the dataset generated by the program will add real-world experience to the controlled trial record.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.